The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

intarcia.com

Founded Year

1995

Stage

Debt - VI | Alive

Total Raised

$1.487B

Valuation

$0000 

Last Raised

$198.5M | 3 yrs ago

About Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

Intarcia Therapeutics Headquarter Location

One Marina Park Drive 13th Floor

Boston, Massachusetts, 02210,

United States

617-936-2500

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Intarcia Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Intarcia Therapeutics in 2 CB Insights research briefs, most recently on Mar 29, 2022.

Expert Collections containing Intarcia Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Intarcia Therapeutics is included in 4 Expert Collections, including Unicorns- Billion Dollar Startups.

U

Unicorns- Billion Dollar Startups

1,118 items

M

Medical Devices

8,082 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

H

Health IT

7,900 items

Intarcia Therapeutics Patents

Intarcia Therapeutics has filed 79 patents.

The 3 most popular patent topics include:

  • Diabetes
  • Drug delivery devices
  • Dosage forms
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/14/2019

2/15/2022

G protein coupled receptors, Diabetes, Peptide hormones, Sodium compounds, Potassium compounds

Grant

Application Date

6/14/2019

Grant Date

2/15/2022

Title

Related Topics

G protein coupled receptors, Diabetes, Peptide hormones, Sodium compounds, Potassium compounds

Status

Grant

Latest Intarcia Therapeutics News

Intarcia may finally get its post-CRL review, although FDA points to Covid and another hearing as taking priority

Mar 25, 2022

Zachary Brennan Senior Editor Intarcia Therapeutics, once valued at more than $5 billion and attracting investors like the Bill & Melinda Gates Foundation, is now tussling with the FDA’s drug advisors over a last-ditch hearing to discuss the agency’s second rejection of the company’s lead type 2 diabetes drug since 2017. Back in December, Intarcia’s lawyer sent a letter to the FDA requesting that the agency set up a hearing to discuss this complete response letter, which laid out clinical deficiencies and device and product quality-related issues for the drug, known as ITCA 650. The agency in September granted the hearing but the schedule for it has yet to be established, and the agency is now making clear that this hearing is not its first priority. In a March 22 letter from Donna Katz of FDA’s Office of Chief Counsel to Matthew Warren, director of FDA’s Office of Scientific Integrity, Katz explained how CDER and Intarcia met via teleconference on March 14 but were unable to reach an agreement on the timing for CDER to submit its analysis and proposed order. Katz explains how ITCA 650 is a combo product, so CDRH officials will need to be involved. And not only are CDER employees still tied up with Covid-related work, but there’s another request for a hearing that will take precedence over Intarcia’s, as it was submitted earlier from Lexicon Pharmaceuticals. Lexicon received a CRL on March 3, 2021, for its sotagliflozin oral tablets for use as an adjunct to insulin therapy to improve glycemic control in adults with Type 1 diabetes. “CDER requests that any deadline established by the Commissioner regarding Intarcia’s hearing request be after any deadline established in that other hearing proceeding, and no earlier than July 29, 2022,” Katz wrote. She also requests later in the letter that Commissioner Rob Califf remain open to considering a request for an extension of time if needed due to unforeseen circumstances. For the ITCA 650 submission, which Katz noted was recently supplemented on Feb. 15, the road ahead looks murky, particularly as the company has been dealt three prior rejections of formal dispute resolution requests on top of the two CRLs. Intarcia’s CEO Kurt Graves told Endpoints News that the FDA diabetes division’s central non-approval claim against ITCA 650 is that it is the only GLP-1 “with a small and non-significant numeric imbalance in AKI events observed in a controlled clinical trial setting. The division has maintained that no other GLP-1 controlled clinical trials have ever observed similarly small AKI imbalances – even though they all have class labeled AKI Warnings and Precautions.” Graves pointed to Novo Nordisk’s AKI data for its diabetes drug Wegovy as FDA’s “own clinical review documents for the approval of Wegovy highlight an identical numeric imbalance in serious AKI events (not favoring drug) on Wegovy in their controlled trial package that supported Wegovy’s approval with labeled AKI Warnings. The only difference vs. ITCA 650 here is the FDA reviewer on ITCA 650 deemed the small and identical AKI imbalance a non-approval issue that couldn’t be labeled….where the review team on Wegovy (and all the other approved GLP-1s) deemed the AKI imbalances a labeling issue and approved the product/s with GLP-1 class labeled AKI warnings.” But the FDA previously raised questions about how trial participants who received ITCA 650 “sometimes resulted in prolonged hospitalization; complications observed in association with AKI events included dialysis and death.” A majority of the serious adverse events in participants randomized to ITCA 650 “appeared to be associated with vomiting, diarrhea, and dehydration, which are known adverse reactions associated with exenatide therapy, supporting a causal relationship between ITCA 650 and AKI,” FDA said. In addition, FDA said the company failed to provide sufficient assurances that its experimental diabetes drug is not linked to excess cardiovascular risks. And an FDA inspection of the Intarcia manufacturing facility also “identified deficiencies with the manufacturing practices for ITCA 650 that were not adequately addressed,” the agency said. Editor’s note: Article updated with new comments from Intarcia CEO Kurt Graves. AUTHOR Did the FDA change its mind about the class of cancer drugs known as PI3K? Whereas the agency had previously granted accelerated approvals to PI3K drugs, that option is apparently off the table for zandelisib, a candidate from MEI Pharma and Kyowa Kirin. For the companies, that means delaying a potential monotherapy launch from 2023 to 2026, according to analysts. There has been considerable heat around the drug class as Gilead yanked its PI3K inhibitor from the market, Incyte withdrew its NDA and the FDA put some of TG Therapeutics’ clinical work on its PI3K drug on hold, citing a potential increased risk of death. Keep reading Endpoints with a free subscription Unlock this story instantly and join 136,900+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Max Gelman Editor Over the last 24 hours, something strange has happened in biotech: Public companies are raising money — and quite a lot, at that. Following Nasdaq’s closing bell Wednesday afternoon, three biotechs announced nine-figure raises in Ascendis Pharma, argenx and Apellis Pharmaceuticals, at a time where a bear market continues to bludgeon the sector. While unexpected, the cash sent a signal that companies can still pull together funds at the right opportunity, independent investor Brad Loncar told Endpoints News. Keep reading Endpoints with a free subscription Unlock this story instantly and join 136,900+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Kyle LaHucik Associate Editor Bristol Myers Squibb was supposed to find out by this Sunday if the FDA was OK with a third approval for its Celgene-acquired, Acceleron-partnered anemia drug Reblozyl. But “a major amendment” is putting a bump in those plans. The Big Pharma will have to wait another three months, possibly as far out as June 27, to see if the agency will greenlight a supplemental nod. Bristol Myers wants Reblozyl — one of four drugs that the company anticipates could eventually rack up $4 billion in revenue per year — to also be a treatment for anemia in adults with non-transfusion-dependent (NTD) beta thalassemia. Read More March 23, 2022 07:02 AM EDTUpdated 02:54 PM Max Gelman Editor Next week, an FDA advisory committee will face an all-too familiar question: Should a drug for a fatal, neurodegenerative disease be approved despite less than conclusive efficacy data? It hasn’t been two full years since the panel faced a similar question in Biogen’s Alzheimer’s drug aducanumab. And it’s not unlike the 2016 debate over Sarepta’s first muscular dystrophy drug, either. In both scenarios, the FDA’s outside experts recommended against approval — unanimously in Biogen’s case — and in both scenarios, the agency greenlighted the drugs. Keep reading Endpoints with a free subscription Unlock this story instantly and join 136,900+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Zachary Brennan Senior Editor The FDA sent over a quick rejection letter on Thursday to Eli Lilly regarding its anti-PD-1 antibody sintilimab, further crushing the hopes of any companies looking to bring cheaper follow-ons based only on Chinese data. The complete response letter (CRL) follows a nearly unanimous Oncologic Drugs Advisory Committee (ODAC) recommendation against sintilimab’s approval, which was intended as a first-line treatment for people with nonsquamous non-small cell lung cancer. The FDA also revealed at the meeting that the company submitted the application without consulting regulators before the trial concluded, and misrepresented interactions with the agency during its presentation. Keep reading Endpoints with a free subscription Unlock this story instantly and join 136,900+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Nicole DeFeudis Editor Just over a year after it was initially approved, GSK’s HIV unit ViiV Healthcare has found yet another way to make Cabenuva’s label even more attractive. Cabenuva consists of two extended-release injectables: cabotegravir, which is developed by ViiV, and rilpivirine from J&J’s Janssen which is also marketed individually under the brand names Edurant and Rekambys. Previously, patients starting out on the long-acting HIV treatment were required to first take cabotegravir and rilpivirine by mouth for one month to assess their tolerability of the medicines before moving on to injections. Read More March 24, 2022 01:52 PM EDTUpdated 02:24 PM Jason Mast Editor When Longxing Cao arrived as a postdoc at the University of Washington in 2017, David Baker’s lab was already known as the leader in a niche field of designing new proteins from scratch. The idea was to replace, or supplement, the usual method for designing new proteins, i.e. borrowing from evolution. To come up with most new biologic therapies for cancer or infectious disease, for example, researchers generally filter out the best antibodies mice or humans develop against a virus or bits of a tumor. Maybe they’ll tinker with it a little. Keep reading Endpoints with a free subscription Unlock this story instantly and join 136,900+ biopharma pros reading Endpoints daily — and it's free. SIGN UP LOG IN

Intarcia Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Intarcia Therapeutics Rank

  • When was Intarcia Therapeutics founded?

    Intarcia Therapeutics was founded in 1995.

  • Where is Intarcia Therapeutics's headquarters?

    Intarcia Therapeutics's headquarters is located at One Marina Park Drive, Boston.

  • What is Intarcia Therapeutics's latest funding round?

    Intarcia Therapeutics's latest funding round is Debt - VI.

  • How much did Intarcia Therapeutics raise?

    Intarcia Therapeutics raised a total of $1.487B.

  • Who are Intarcia Therapeutics's competitors?

    Competitors of Intarcia Therapeutics include Zogenix, Adamas Pharmaceuticals, Diasome Pharmaceuticals, CoImmune, Annovis Bio, Embera NeuroTherapeutics, Aerogen, Metabolic Solutions Development, Soleno Therapeutics, Bellus Health and 84 more.

You May Also Like

H
Humanetics Corporation

Humanetics Corporation is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs with a focus on radiation modulators for oncology, medical imaging and medical countermeasure uses.

A
Actinobac Biomed

Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.

M
MacuSight

MacuSight is a privately-held pharmaceutical company focused on developing innovative therapeutics for the treatment of severe ocular diseases and conditions. The company is dedicated to preserving patients' vision by identifying known, highly-potent and broad-acting small molecule drug compounds that may possess efficacy in treating and/or preventing diseases or conditions of the eye. As part of its unique product development philosophy, MacuSight also concentrates on the optimal delivery of these compounds into the eye. By combining its compounds with innovative delivery approaches, the company strives to optimize the efficacy, safety, convenience and cost-effectiveness of its product candidates.

N
Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.

I
INDENA SPA

Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.

T
Traversa Therapeutics

Traversa Therapeutics is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi anti-cancer therapeutics. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of platform delivery technology, as well as advancement of therapeutic programs for the treatment of leukemia and glioblastoma.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.